Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Izuralimab (XmAb23104) in Advanced Solid Tumors
NCT03752398Phase 1Completed
- Sponsor
- Xencor
- Start
- May 2019
- Primary completion
- Feb 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of izuralimab in solid tumor (advanced stage) (2 arms), sponsored by Xencor. Primary endpoint: Treatment-related adverse events at 56 Days. Started May 2019; status: completed.
02
Drugs
izuralimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03752398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03752398.